共 33 条
- [22] HDAC inhibitor ITF2357 reduces resistance of mutant-KRAS non-small cell lung cancer to pemetrexed through a HDAC2/miR-130a-3p-dependent mechanism Journal of Translational Medicine, 21
- [25] BIOMARKER ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF ERLOTINIB WITH AND WITHOUT ENTINOSTAT, A CLASS 1 ISOFORM SELECTIVE HISTONE DEACETYLASE INHIBITOR (HDAC) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC; ENCORE-401) JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S607 - S608
- [26] ANALYSIS OF CROSS-OVER PORTION OF ENCORE-401, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF ERLOTINIB WITH AND WITHOUT ENTINOSTAT, A CLASS 1 ISOFORM SELECTIVE HISTONE DEACETYLASE INHIBITOR (HDAC) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1314 - S1314
- [27] miR-136 Suppresses the Aggressive Proliferation of Non-Small Cell Lung Cancer Through Restraining Histone Deacetylase 1 (HDAC1) and Phosphorylation of the Janus Kinase 2/Signal Transducer and Activator of Transcription 3 (Jak2/STAT3) Pathway JOURNAL OF BIOMATERIALS AND TISSUE ENGINEERING, 2022, 12 (04) : 763 - 769